Skip to content
KPV Store

A friendly, plain-spoken digest of the KPV peptide literature — what the anti-inflammatory and wound-healing research on this alpha-MSH tripeptide actually shows, and where compounded access really stands.

The papers and FDA pages cited here

The numbered list shows the source for each finding

Each entry names the study team, the test they ran, or the FDA page that explains a rule.

Return to the study resultsRead the short answers

These papers report cell and animal studies

KPV is a peptide, made by linking three protein parts from a body hormone. Researchers hoped those parts would reduce swelling. They wanted to avoid the hormone’s skin-darkening effect, and the papers below show you what happened next. Every KPV test listed here used cells or animals. No published human trial appears because researchers have not reported one [13]. PubMed is a U.S. government list of medical papers, while Crossref is a list kept by publishers. PMID and DOI are lookup codes that help you open the right paper.

The FDA pages show the meeting and the current limit

FDA advisers met in July 2026. Staff opposed putting raw KPV on the approved ingredient list for pharmacies, and FDA had posted no final vote. The KPV legal status page gives you the practical answer.

  1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. ↗
  2. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. ↗
  3. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. ↗
  4. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. ↗
  5. Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. ↗
  6. Bonfiglio V, Camillieri G, Avitabile T, Leggio GM, Drago F. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res. 2006;83(6):1366-1372. ↗
  7. Böhm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing? Exp Dermatol. 2019;28(3):219-224. ↗
  8. Zhou F, et al. In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect. Biomater Sci. 2022;10(7):1644-1655. ↗
  9. Zhao Y, et al. Skin-adaptive film dressing with smart-release of growth factors accelerated diabetic wound healing. Int J Biol Macromol. 2022;222(Pt A):1738-1748. ↗
  10. Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review. Int J Med Sci. 2025. ↗
  11. Catania A, Cutuli M, Garofalo L, et al. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133-140. ↗
  12. Zhang D, et al. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combination treatment of acute and chronic DSS-induced colitis. Front Pharmacol. 2024;15:1442876. ↗
  13. KPV compound corpus (rev. 2): compiled dosage-context, stability, and human-data status. KPV is a small peptidase-labile tripeptide with no published human clinical trials and no validated human pharmacokinetics; it is a research-only chemical not approved for human use by any regulator. Synthesizes the primary literature cited here (Dalmasso 2008; Kannengiesser 2008; Bonfiglio 2006; Xiao 2017; Brzoska 2008). ↗
  14. Lin X, et al. KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy. Adv Healthc Mater. 2024. ↗
  15. Ji HX, Zou YL, Duan JJ, et al. The synthetic melanocortin (CKPV)2 exerts anti-fungal and anti-inflammatory effects against Candida albicans vaginitis via inducing macrophage M2 polarization. PLoS One. 2013;8(2):e56004. ↗
  16. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (FDA's nominated-substances / significant-safety-risks compounding page; cited here for the 503A bulk-substance framework. KPV is not an FDA-approved drug.) Verified 2026-05-29. ↗
  17. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (503A/503B framework; bulk-substance eligibility — USP/NF monograph, component of an approved drug, or bulks-list inclusion; public nomination with PCAC input; January 7, 2025 revised interim policy.) Verified 2026-05-29. ↗
  18. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (BPC-157, KPV, TB-500, and MOTs-C listed as bulk drug substances being considered for inclusion on the 503A Bulks List; KPV evaluated in free-base and acetate forms — a scheduled discussion, not a decision.) Verified 2026-05-29. ↗
  19. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance landing page; finalized January 2025). Verified 2026-05-29. ↗